home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9410l.zip
/
M94A2018.TXT
< prev
next >
Wrap
Text File
|
1994-10-24
|
2KB
|
30 lines
Document 2018
DOCN M94A2018
TI The dilemma of developing a vaccine against HIV.
DT 9412
AU Bolognesi DP; Duke University Medical Center, Durham, NC.
SO Int Conf AIDS. 1994 Aug 7-12;10(1):4 (abstract no. PS4). Unique
Identifier : AIDSLINE ICA10/94370557
AB Despite an unprecedented research and development effort that has been
ongoing since the mid 1980's the quest for a vaccine against HIV has and
continues to experience a pattern of unsteady progress. Animal model
studies have not produced uniform guiding principles but rather a
complex and often confusing picture. Frustrated, vaccine developers have
turned to man as the experimental model but here too unanticipated
obstacles have stymied progress. With over a dozen vaccine candidates in
clinical trials including two in Phase II studies and an infrastructure
being prepared to accept vaccines for large scale efficacy trials, the
HIV vaccine field is at a crossroads, with forward movement difficult in
the absence of clear correlates of immunity. At the same time several
new developments stemming from studies of HIV pathogenesis may help
point the way toward a better understanding of correlates of protection
and with several promising vaccine strategies under development, the
outlook for eventual success remains plausible. These and other issues
related to HIV vaccines will be discussed.
DE Acquired Immunodeficiency Syndrome/PREVENTION & CONTROL AIDS
Vaccines/*ISOLATION & PURIF Human HIV/*IMMUNOLOGY MEETING ABSTRACT
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).